Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MOK | Q9UQ07 | 9/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466395 | 0.83 | PARP1 (0.50) | HDAC1KDM4EHTTALDH1A1 | |
| SCHEMBL6506559 | 0.80 | PARP1 (0.55) | HDAC1KDM4EHTT | |
| SCHEMBL6507516 | 0.78 | ITK (0.48) | HDAC1HDAC2HDAC3KDM4EITK | |
| SCHEMBL6499042 | 0.73 | KDM4E (0.49) | KDM4EHTTITKALDH1A1 | |
| SCHEMBL6497388 | 0.73 | KDM4E (0.53) | KDM4EHTTITKALDH1A1 | |
| SCHEMBL26773139 | 0.71 | ALDH1A1 (0.56) | CYP2C9CYP2C19KDM4EHTTALDH1A1 | |
| SCHEMBL30486279 | 0.71 | ALDH1A1 (0.56) | CYP2C9CYP2C19KDM4EHTTALDH1A1 | |
| SCHEMBL6499137 | 0.70 | ITK (0.48) | KDM4EHTTITKALDH1A1 | |
| SCHEMBL6500409 | 0.69 | ITK (0.55) | CYP3A4KDM4EHTTITKALDH1A1 | |
| SCHEMBL6500705 | 0.69 | MEN1 (0.44) | KDM4EHTTITKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | HDAC1 462/4885CYP3A4 64/4885CYP2D6 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.